RBC Capital raised the firm’s price target on AdaptHealth (AHCO) to $14 from $11 and keeps an Outperform rating on the shares after its Q4 earnings beat. The company saw a strong finish to 2024 and gave solid initial guidance, the analyst tells investors in a research note. Early signs that the strategic overhaul to the Diabetes business announced last quarter may be taking hold, the firm adds.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AHCO: